ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 991

Identification of Citrullinated Peptide Specific T-cells in Humanized Mice Immunized with Citrullinated Peptides

Matthew McElwee1, Thamotharampillai Dileepan 1 and Marc Jenkins 1, 1University of Minnesota, Minneapolis, MN

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Animal models, citrullination, Mouse model, rheumatoid arthritis, T cells and shared epitope

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Animal Models Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Seropositive rheumatoid arthritis (RA) is a T-cell mediated disease that is characterized by the presence of antibodies to proteins that have undergone the post-translational conversion of arginine to citrulline. Certain HLA-DR major histocompatibility complex class II (MHCII) molecules, for example HLA-DRB1*0401 are closely associated with the development of seropositive RA. These molecules prefer to bind peptides with citrulline not arginine in the P4 position. Thus, citrullination of arginine can create peptides that bind to HLA-DRB1*0401 molecules better than the un-citrullinated versions.  These citrullinated peptide:HLA-DRB1*0401 complexes may form neo-antigens that activate T-cells with specific T-cell receptors. Indeed, such cells have been identified in patients with RA.
In this study, we investigated the correlation between the reported binding affinity of citrullinated peptides to HLA-DRB1*0401 molecules (Ting et al.) and the number of T-cells that recognize these complexes after immunization with citrullinated peptide in transgenic mice expressing HLA-DRB1*0401 molecules.

Methods: Mice expressing HLA-DRB*0401 were immunized with 100 mg of one of eleven citrullinated peptides. The citrullinated peptides tested all had a citrulline at the P4 position and were from human proteins known to have citrullinated antibodies raised against them in RA. These proteins were: collagen intermediate layer protein (2 peptides), fibrinogen (2 peptides), vimentin (3 peptides), LL37 (1 peptide), a-enolase (1 peptide), and aggrecan (2 peptides). Ten days after immunization, citrullinated peptide:HLA-DRB1*0401 tetramers were used to identify specific T-cells in secondary lymphoid organs by flow cytometry.

Results: There was a wide range in the number of citrullinated peptide:HLA-DRB1*0401 tetramer-binding cells isolated from immunized mice (43-5557). The peptide that generated the lowest number of tetramer-binding cells was from human aggrecan 89-103 (Cit95) and the highest number was from human fibrinogen 69-81 (Cit74). When analyzing all peptides, there was a significant correlation between the affinity of the peptide for HLA-DRB1*0401 and the log10 number of citrullinated peptide:MHC tetramer positive cells identified after immunization (R squared 0.454, p< 0.03)

Conclusion: Immunization with citrullinated peptides with higher binding affinity to an RA-associated MHCII molecule stimulated a greater number of specific T-cells. These results provide further evidence that citrullination enhances T cell immunogenicity by improving the capacity of peptides to bind MHCII molecules.


Disclosure: M. McElwee, None; T. Dileepan, None; M. Jenkins, None.

To cite this abstract in AMA style:

McElwee M, Dileepan T, Jenkins M. Identification of Citrullinated Peptide Specific T-cells in Humanized Mice Immunized with Citrullinated Peptides [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/identification-of-citrullinated-peptide-specific-t-cells-in-humanized-mice-immunized-with-citrullinated-peptides/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-citrullinated-peptide-specific-t-cells-in-humanized-mice-immunized-with-citrullinated-peptides/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology